Seelos Therapeutics (SEEL.Q) Proxy Filing summary

Executive summary

• Annual Meeting of Stockholders postponed to November 25, 2024, due to anticipated lack of quorum and to allow more time for proxy solicitation.

• Record date for voting remains August 19, 2024; prior votes remain valid unless changed by stockholders.

• Company focuses on developing therapies for central nervous system disorders and rare diseases.

• Forward-looking statements highlight risks including stockholder approval, capital raising, and stock price volatility.

Voting matters and shareholder proposals

• Board unanimously recommends voting FOR all director nominees and proposals listed in the proxy statement.

• Stockholders are urged to vote promptly to ensure their shares are counted at the postponed meeting.

Board of directors and corporate governance

• Directors, executive officers, and management are actively participating in proxy solicitation.

• Information on directors' and officers' security holdings is available in the definitive proxy statement and SEC filings.